Developing and deploying genomics technologies in support of cancer and life sciences research.

Canada's Michael Smith Genome Sciences Centre (GSC) at BC Cancer is an international leader in genomics, proteomics and bioinformatics for precision medicine. By developing and deploying cutting-edge genome sequencing, computational and analytical technology, we are creating novel strategies to prevent and diagnose cancers and other diseases, uncovering new therapeutic targets and helping the world realize the social and economic benefits of genome science. 

Technology Platform

The GSC is available to support your research. We guide experimental design, facilitate the processing of complex biological samples and provide numerous sequencing and bioinformatic services with the aim of making genomics accessible to the international scientific community. Explore our technology platforms and services, and if you have questions or would like to collaborate please fill out our contact form or speak directly with one of our platform leaders.

The GSC is ISO27001 certified for information security management.

Scientific Research

The 15 faculty members at the GSC have a diverse range of expertise in genomics, bioinformatics, proteomics, epigenomics, immunogenetics, cancer biology, computer science and software development. Together, we apply our knowledge to advance the global understanding of cancer and other diseases with an ultimate aim toward improving human health through disease prevention, the development of novel diagnostic strategies and by uncovering new therapeutic approaches, all the while helping the world to realize the social and economic benefits of genome research.

Clinical Programs

The GSC is unique in that it fosters close collaborations between scientists and clinicians, allowing for an unencumbered focus on direct translational research. Through the Personalized OncoGenomics (POG) program, the GSC deploys whole genome and transcriptome sequencing to inform therapeutic and management strategies for late-stage cancer patients in real time. The GSC is also certified by the College of American Pathologists (CAP) and the Diagnostic Accreditation Program (DAP) to perform clinical genomic panel testing.


Please feel free to speak with one of our Platform Leaders directly:

Directors & Platform Leaders


Mar 18, 2021

A new method for analyzing silenced genes

Cancers are diseases of the genome. They can result from minor changes to single or a few base pairs, known as mutations, or from larger structural changes to the genome, including how it is packaged into chromosomes and manipulated by other molecules. Understanding how things have gone wrong in specific cancers can help scientists develop better prognostic tools and treatment strategies.


A Scalable Strand-Specific Protocol Enabling Full-Length Total RNA Sequencing From Single Cells

Frontiers in Genetics
Simon Haile, Richard D. Corbett, Veronique G. LeBlanc, Lisa Wei, Stephen Pleasance, Steve Bilobram, Ka Ming Nip, Kirstin Brown, Eva Trinh, Jillian Smith, Diane L. Trinh, Miruna Bala, Eric Chuah, Robin J. N. Coope, Richard A. Moore, Andrew J. Mungall, Karen L. Mungall, Yongjun Zhao, Martin Hirst, Samuel Aparicio, Inanc Birol, Steven J. M. Jones, Marco A. Marra

Proteomic screens for suppressors of anoikis identify IL1RAP as a promising surface target in Ewing sarcoma

Cancer Discovery, 2021
Hai-Feng Zhang, Christopher S Hughes, Wei Li, Jian-Zhong He, Didier Surdez, Amal M El-Naggar, Hongwei Cheng, Anna Prudova, Alberto Delaidelli, Gian Luca Negri, Xiaojun Li, Maj Sofie Orum-Madsen, Michael M Lizardo, Htoo Zarni Oo, Shane Colborne, Taras Shyp, Renata Scopim-Ribeiro, Colin A Hammond, Anne-Chloe Dhez, Sofya Langman, Jonathan Km Lim, Sonia Hy Kung, Amy Li, Anne Steino, Mads Daugaard, Seth J Parker, Ramon I Klein Geltink, Rimas J Orentas, Li-Yan Xu, Gregg B Morin, Olivier Delattre, Dimiter S Dimitrov, Poul H Sorensen
Back to top